Key result
Simultaneous PET/MRI supported clinical decision-making and provided meaningful diagnostic information in three cases of soft-tissue sarcoma.
Why the study?
Does simultaneous PET/MRI support clinical decision-making in patients with high-risk soft-tissue sarcoma?
Case Report (n=3)
Does simultaneous PET/MRI support clinical decision-making in patients with high-risk soft-tissue sarcoma?
Simultaneous PET/MRI may be a useful hybrid imaging modality to support clinical decision-making in patients with high-risk soft-tissue sarcoma.
Answers are grounded in this paper and cite their sources.
May inform decisions in high-risk soft-tissue sarcoma; hypothesis-generating and requires prospective validation.
Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is a new whole-body hybrid PET/MR imaging technique that combines metabolic and cross-sectional diagnostic imaging. Since the use of MRI in imaging of soft-tissue sarcoma is extremely beneficial, investigation of the combined PET/MRI is of great interest. In this paper, we present three cases and first data. Combined PET/MRI technique can support the process of clinical decision-making and give answers to some meaningful questions when treating patients with STS. Therefore, the combined modality of simultaneous PET/MRI offers new pieces to the puzzle of sarcoma treatment.
No takes yet. Share an insight, caveat, or question.
Schuler et al. (2013) conducted a case report in Soft-tissue sarcoma (n=3). Simultaneous PET/MRI was evaluated. Simultaneous PET/MRI supported clinical decision-making and provided meaningful diagnostic information in three cases of soft-tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: